Search results for "anticancer compound"

showing 5 items of 5 documents

A compound-based proteomic approach discloses 15-ketoatractyligenin methyl ester as a new PPARγ partial agonist with anti-proliferative ability

2017

AbstractProteomics based approaches are emerging as useful tools to identify the targets of bioactive compounds and elucidate their molecular mechanisms of action. Here, we applied a chemical proteomic strategy to identify the peroxisome proliferator-activated receptor γ (PPARγ) as a molecular target of the pro-apoptotic agent 15-ketoatractyligenin methyl ester (compound 1). We demonstrated that compound 1 interacts with PPARγ, forms a covalent bond with the thiol group of C285 and occupies the sub-pocket between helix H3 and the β-sheet of the ligand-binding domain (LBD) of the receptor by Surface Plasmon Resonance (SPR), mass spectrometry-based studies and docking experiments. 1 displayed…

Transcriptional Activation0301 basic medicinenatural productTime FactorsPeroxisome proliferator-activated receptorApoptosisLigandsPartial agonistArticleRosiglitazonePPAR_gammaJurkat Cells03 medical and health sciencesTransactivation0302 clinical medicineproteomicsHumansBinding siteReceptorMode of actionPI3K/AKT/mTOR pathwayCell Proliferationchemistry.chemical_classificationBinding SitesMultidisciplinaryProtein StabilityProtein Proliferator-Activated-Receptor PPARs Ligand-Binding Domain Chemical Proteomics Accurate Docking Pi3k/Akt Pathway Drug Discovery Anticancer compoundsReproducibility of ResultsEstersSurface Plasmon ResonanceMolecular Docking SimulationPPAR gammaKineticsHEK293 Cells030104 developmental biologychemistryBiochemistryDocking (molecular)030220 oncology & carcinogenesisThermodynamicsThiazolidinedionesproteomics PPAR_gamma natural productDiterpenes KauraneHT29 CellsScientific Reports
researchProduct

Marine Animal-Derived Compounds and Autophagy Modulation in Breast Cancer Cells

2021

It is known that in breast cancer biology, autophagy mainly plays a cytoprotective and anti-apoptotic role in vitro, being conceivably responsible for cell resistance to drug exposure and a higher metastatic attitude in vivo. Thus, the development of novel autophagy-targeting agents represents a valuable strategy to improve the efficacy of anticancer interventions. It is widely acknowledged that the enormous biodiversity of marine organisms represents a highly promising reserve for the isolation of bioactive primary and secondary metabolites targeting one or several specific molecular pathways and displaying active pharmacological properties against a variety of diseases. The aim of this re…

Drugautophagymedia_common.quotation_subjectechinodermsAutophagymolluskBiologymedicine.diseaseapoptosiIn vitroanticancer compoundbreast cancerBreast cancermarine invertebrateApoptosisIn vivoCancer researchmedicinecytotoxicityIdentification (biology)Settore BIO/06 - Anatomia Comparata E CitologiacnidarianCytotoxicitydemospongemedia_commonFoundations
researchProduct

Histone Deacetylase Inhibitors

2020

Histone deacetylases (HDACs) are key components of the epigenetic machinery controlling gene expression. They are involved in chromatin remodeling events via post-translational histone modifications but may also act on nonhistone proteins, influencing many fundamental cellular processes. Due to the key involvement of HDACs in serious human pathologies, including cancer, HDAC inhibitors (HDACis) have received increased attention in recent years. It is known that marine invertebrates produce significant amounts of secondary metabolites showing active pharmacological properties and an extensive spectrum of biomedical applications. Some of these compounds possess HDACi properties.

anticancer compoundCnidariamarine invertebratebiomedical applicationSettore BIO/06 - Anatomia Comparata E Citologiahistone deacetylase inhibitorPoriferaEchinodermata
researchProduct

Histone Deacetylase Inhibitors from Marine Invertebrates

2020

Simple Summary Histone deacetylases (HDACs) are enzymes that control gene expression and are involved in the onset of serious human pathologies, including cancer; hence, their inhibitors (HDACis) have received increased attention in recent years. It is known that marine invertebrates produce significant amounts of molecules showing active pharmacological properties and an extensive spectrum of biomedical applications. This review is focused on the description of the molecular, biochemical, and, where available, physiological aspects of marine invertebrate-derived compounds that possess HDACi properties, taking into consideration their possible utilization as treatment agents against differe…

0301 basic medicineGene isoformbiomedical applicationsmarine invertebratesSettore BIO/05 - ZoologiaComputational biologyReviewhistone deacetylase inhibitorsGeneral Biochemistry Genetics and Molecular BiologyChromatin remodelinganticancer compound03 medical and health sciencesCnidaria0302 clinical medicineNon-histone proteinmarine invertebrateGene expressionEpigeneticsSettore BIO/06 - Anatomia Comparata E Citologiahistone deacetylase inhibitorlcsh:QH301-705.5General Immunology and MicrobiologybiologyMarine invertebratesanticancer compoundsPorifera030104 developmental biologyHistonelcsh:Biology (General)030220 oncology & carcinogenesisbiology.proteinbiomedical applicationHistone deacetylaseGeneral Agricultural and Biological SciencesEchinodermataBiology
researchProduct

In Silico Design, Synthesis and Biological Evaluation of Anticancer Arylsulfonamide Endowed with Anti-Telomerase Activity

2022

Telomerase, a reverse transcriptase enzyme involved in DNA synthesis, has a tangible role in tumor progression. Several studies have evidenced telomerase as a promising target for developing cancer therapeutics. The main reason is due to the overexpression of telomerase in cancer cells (85–90%) compared with normal cells where it is almost unexpressed. In this paper, we used a structure-based approach to design potential inhibitors of the telomerase active site. The MYSHAPE (Molecular dYnamics SHared PharmacophorE) approach and docking were used to screen an in-house library of 126 arylsulfonamide derivatives. Promising compounds were synthesized using classical and green methods. Com…

SulfonamidesRPharmaceutical ScienceAnticancer compounds; Arylsulfonamide; Docking; Molecular dynamics; Pharmacophore modeling; Structure-based drug design; Sulfonamides; Telomerase inhibitorsMolecular dynamicsSettore CHIM/08 - Chimica FarmaceuticaArticleDockingRS1-441Anticancer compoundsTelomerase inhibitorsPharmacy and materia medicaDrug DiscoveryArylsulfonamideMedicineMolecular Medicinesulfonamides; arylsulfonamide; anticancer compounds; telomerase inhibitors; structure-based drug design; pharmacophore modeling; docking; molecular dynamicsStructure-based drug designPharmacophore modeling
researchProduct